The PPARα/γ dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats

British Journal of Pharmacology

Volumn 148, Issue 5, 2006, Pages 610-618

  Li, Ping Ping ^a   Shan, Song ^b   Chen, Yue Teng ^a   Ning, Zhi Qiang ^b   Sun, Su Juan ^a   Liu, Quan ^a   Lu, Xian Ping ^b   Xie, Ming Zhi ^a   Shen, Zhu Fang ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

^b Shenzhen Chipscreen Biosciences Ltd   (China)

Author keywords

Euglycemic clamp; Insulin sensitizer; Peroxisome proliferator activated receptor; Type II diabetes

Indexed keywords

ACYL COENZYME A DEHYDROGENASE; ALANINE; CARNITINE PALMITOYLTRANSFERASE; CHIGLITAZAR; CHOLESTEROL; CYTOCHROME P450 4A; CYTOCHROME P450 4A10; ENOYL COENZYME A HYDRATASE; FATTY ACID; GLUTAMATE SODIUM; GLYCOGEN; INSULIN; ISOPHANE INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROPIONIC ACID DERIVATIVE; ROSIGLITAZONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; CARBAZOLE DERIVATIVE; PIOGLITAZONE; PIRINIXIC ACID; PYRIMIDINE DERIVATIVE;

ADIPOCYTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; DRUG STRUCTURE; DYSLIPIDEMIA; EUGLYCEMIC HYPERINSULINEMIC CLAMP; FATTY ACID BLOOD LEVEL; FIBROSIS; GLUCONEOGENESIS; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; LIPID METABOLISM; LIPID STORAGE; NONHUMAN; NUCLEOTIDE SEQUENCE; PANCREAS ISLET; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TRIACYLGLYCEROL BLOOD LEVEL; ADIPOSE TISSUE; ANIMAL; BLOOD; CHEMICALLY INDUCED DISORDER; CHEMISTRY; COMPARATIVE STUDY; CYTOLOGY; DRUG POTENTIATION; EVALUATION; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLYCOGEN LIVER LEVEL; LIVER; MUSCLE; OBESITY; PANCREAS; WISTAR RAT;

ADIPOSE TISSUE; ANIMALS; BLOOD GLUCOSE; CARBAZOLES; DISEASE MODELS, ANIMAL; DYSLIPIDEMIAS; GENE EXPRESSION; GLUCONEOGENESIS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIPIDS; LIVER; LIVER GLYCOGEN; MUSCLES; OBESITY; PANCREAS; PPAR ALPHA; PPAR GAMMA; PROPIONIC ACIDS; PYRIMIDINES; RATS; RATS, WISTAR; SODIUM GLUTAMATE; THIAZOLIDINEDIONES;

EID: 33745606757     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706745     Document Type: Article

References (36)

1. AHREN, B. (2005). Type 2 diabetes, insulin secretion and beta-cell mass. Curr. Mol. Med., 5, 275-286.
2. ARONOFF, S., ROSENBLATT, S., BRAITHWAITE, S., EGAN, J.W., MATHISEN, A.L. & SCHNEIDER, R.L. (2000). Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diab. Care, 23, 1605-1611.
3. BERTHIAUME, M., SELL, H., LALONDE, J., GELINAS, Y., TCHERNOF, A., RICHARD, D. & DESHAIES, Y. (2004). Actions of PPARgamma agonism on adipose tissue remodeling, insulin sensitivity, and lipemia in absence of glucocorticoids. Am. J. Physiol. Regul. Integr. Comp. Physiol., 287, R1116-R1123.
4. BODEN, G. (2002). Interaction between free fatty acids and glucose metabolism. Curr. Opin. Clin. Nutr. Metab. Care, 5, 545-549.
5. BRAND, C.L., STURIS, J., GOTFREDSEN, C.F., FLECKNER, J., FLEDELIUS, C., HANSEN, B.F., ANDERSEN, B., YE, J.M., SAUERBERG, P. & WASSERMANN, K. (2003). Dual PPARalpha/gamma activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats. Am. J. Physiol. Endocrinol. Metab., 284, E841-E854.
6. CAMPBELL, I.W. (2005). The clinical significance of PPAR gamma agonism. Curr. Mol. Med., 5, 349-363.
7. CHIASSON, J.L., LILJENQUIST, J.E., LACY, W.W., JENNINGS, A.S. & CHERRINGTON, A.D. (1977). Gluconeogenesis: methodological approaches in vivo. Fed. Proc., 36, 229-235.
8. CHOU, C.J., HALUZIK, M., GREGORY, C., DIETZ, K.R., VINSON, C., GAVRILOVA, O. & REITMAN, M.L. (2002). WY14,643, a peroxisome proliferator-activated receptor alpha (PPARalpha) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice. J. Biol. Chem., 277, 24484-24489.
9. DEVROEY, D., VELKENIERS, B., DUQUET, W. & BETZ, W. (2005). The benefit of fibrates in the treatment of 'bad HDL-C responders to statins'. Int. J. Cardiol., 101, 231-235.
10. DING, S.Y., SHEN, Z.F. & XIE, M.Z. (2001). Preliminary study of insulin resistance induced by neonatal monosodium glutamate treatment in normal Wistar rats. Chinese Pharmacol. Bull., 17, 181-185.
11. ESCHER, P. & WAHLI, W. (2000). Peroxisome proliferator-activated receptors: insight into multiple cellular functions. Mutat. Res., 448, 121-138.
12. ETGEN, G.J., OLDHAM, B.A., JOHNSON, W.T., BRODERICK, C.L., MONTROSE, C.R., BROZINICK, J.T., MISENER, E.A., BEAN, J.S., BENSCH, W.R., BROOKS, D.A., SHUKER, A.J., RITO, C.J., MCCARTHY, J.R., ARDECKY, R.J., TYHONAS, J.S., DANA, S.L., BILAKOVICS, J.M., PATERNITI JR, J.R., OGILVIE, K.M., LIU, S. & KAUFFMAN, R.F. (2002). A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models. Diabetes, 51, 1083-1087.
13. FINEGOOD, D.T., MCARTHUR, M.D., KOJWANG, D., THOMAS, M.J., TOPP, B.G., LEONARD, T. & BUCKINGHAM, R.E. (2001). Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes, 50, 1021-1029.
14. GUERRE-MILLO, M., GERVOIS, P., RASPE, E., MADSEN, L., POULAIN, P., DERUDAS, B., HERBERT, J.M., WINEGAR, D.A., WILLSON, T.M., FRUCHART, J.C., BERGE, R.K. & STAELS, B. (2000). Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J. Biol. Chem., 275, 16638-16642.
15. GUO, Q., SAHOO, S.P., WANG, P.R., MILOT, D.P., IPPOLITO, M.C., WU, M.S., BAFFIC, J., BISWAS, C., HERNANDEZ, M., LAM, M.H., SHARMA, N., HAN, W., KELLY, L.J., MACNAUL, K.L., ZHOU, G., DESAI, R., HECK, J.V., DOEBBER, T.W., BERGER, J.P., MOLLER, D.E., SPARROW, C.P., CHAO, Y.S. & WRIGHT, S.D. (2004). A novel peroxisome proliferator-activated receptor alpha/gamma dual agonist demonstrates favorable effects on lipid homeostasis. Endocrinology, 145, 1640-1648.
16. HAVEL, P.J. (2004). Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. Diabetes, 53 (Suppl 1), S143-S151.
17. HERZ, M., JOHNS, D., REVIRIEGO, J., GROSSMAN, L.D., GODIN, C., DURAN, S., HAWKINS, F., LOCHNAN, H., ESCOBAR-JIMENEZ, F., HARDIN, P.A., KONKOY, C.S. & TAN, M.H. (2003). A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus. Clin. Ther., 25, 1074-1095.
18. HEVENER, A.L., HE, W., BARAK, Y., LE, J., BANDYOPADHYAY, G., OLSON, P., WILKES, J., EVANS, R.M. & OLEFSKY, J. (2003). Muscle-specific Pparg deletion causes insulin resistance. Nat. Med., 9, 1491-1497.
19. HIRATA, A.E., ANDRADE, I.S., VASKEVICIUS, P. & DOLNIKOFF, M.S. (1997). Monosodium glutamate (MSG)-obese rats develop glucose intolerance and insulin resistance to peripheral glucose uptake. Braz. J. Med. Biol. Res., 30, 671-674.
20. HUNDAL, R.S., KRSSAK, M., DUFOUR, S., LAURENT, D., LEBON, V., CHANDRAMOULI, V., INZUCCHI, S.E., SCHUMANN, W.C., PETERSEN, K.F., LANDAU, B.R. & SHULMAN, G.I. (2000). Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes, 49, 2063-2069.
21. KAWASAKI, F., MATSUDA, M., KANDA, Y., INOUE, H. & KAKU, K. (2005). Structural and functional analysis of pancreatic islets preserved by pioglitazone in db/db mice. Am. J. Physiol. Endocrinol. Metab., 288, E510-E518.
22. KERSTEN, S., DESVERGNE, B. & WAHLI, W. (2000). Roles of PPARs in health and disease. Nature, 405, 421-424.
23. KHAN, M.A., ST PETER, J.V. & XUE, J.L. (2002). A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care, 25, 708-711.
24. KRAEGEN, E.W., JAMES, D.E., BENNETT, S.P. & CHISHOLM, D.J. (1983). In vivo insulin sensitivity in the rat determined by euglycemic clamp. Am. J. Physiol., 245, E1-E7.
25. LOVISCACH, M., REHMAN, N., CARTER, L., MUDALIAR, S., MOHADEEN, P., CIARALDI, T.P., VEERKAMP, J.H. & HENRY, R.R. (2000). Distribution of peroxisome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue: relation to insulin action. Diabelologia, 43, 304-311.
26. LUPI, R., DEL GUERRA, S., MARSELLI, L., BUGLIANI, M., BOGGI, U., MOSCA, F., MARCHETTI, P. & DEL PRATO, S. (2004). Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion. Am. J. Physiol. Endocrinol. Metab., 286, E560-E567.
27. MAEGAWA, H., OBATA, T., SHIBATA, T., FUJITA, T., UGI, S., MORINO, K., NISHIO, Y., KOJIMA, H., HIDAKA, H., HANEDA, M., YASUDA, H., KIKKAWA, R. & KASHIWAGI, A. (1999). A new antidiabetic agent (JTT-501) rapidly stimulates glucose disposal rates by enhancing insulin signal transduction in skeletal muscle. Diabetologia, 42, 151-159.
28. MOLLER, D.E. (2001). New drug targets for type 2 diabetes and the metabolic syndrome. Nature, 414, 821-827.
29. MURAKAMI, K., TOBE, K., IDE, T., MOCHIZUKI, T., OHASHI, M., AKANUMA, Y., YAZAKI, Y. & KADOWAKI, T. (1998). A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats. Diabetes, 47, 1841-1847.
30. PETER, P., NUTTALL, S.L. & KENDALL, M.J. (2003). Insulin resistance - the new goal!. J. Clin. Pharm. Ther., 28, 167-174.
31. PRENTKI, M., JOLY, E., EL-ASSAAD, W. & RODUIT, R. (2002). Malonyl-CoA signaling, lipid partitioning, and glucolipotoxicity: role in beta-cell adaptation and failure in the etiology of diabetes. Diabetes, 51 (Suppl 3), S405-S413.
32. ROBINS, S.J. (2001). PPARalpha ligands and clinical trials: cardiovascular risk reduction with fibrates. J. Cardiovasc. Risk., 8, 195-201.
33. STUMVOLL, M., GOLDSTEIN, B.J. & VAN HAEFTEN, T.W. (2005). Type 2 diabetes: principles of pathogenesis and therapy. Lancet, 365, 1333-1346.
34. UNGER, R.H., ZHOU, Y.T. & ORCI, L. (1999). Regulation of fatty acid homeostasis in cells: novel role of leptin. Proc. Natl. Acad. Sci. U.S.A., 96, 2327-2332.
35. WAUGH, J., KEATING, G.M., PLOSKER, G.L., EASTHOPE, S. & ROBINSON, D.M. (2006). Pioglitazone: a review of its use in type 2 diabetes mellitus. Drugs, 66, 85-109.
36. YKI-JARVINEN, H. (2004). Thiazolidinediones. N. Engl. J. Med., 351, 1106-1118.